ICAM1 and systemic lupus erythematosus: These findings reveal the therapeutic potential of RPR in treating SLE and CLE because the expression of adhesion molecules on vascular endothelial cells controls the flow of leukocytes into tissues during an inflammatory response (Malik and Lo, 1996), thus, in order for leukocytes to interact with keratinocytes, ICAM-1 must be involved.